Xi’an Medisotope Technology Co., Ltd.  (short for MSTP) was established in 2019. It is a high-tech company specializing in the research of photonuclear transmutation and nuclear radiation technology, and production of medical isotopes and nuclear medical equipment. The company focuses on the research and development of medical isotopes production such as Actinium-225 (²²⁵Ac),  Lead-212  (²¹²Pb), Copper-67 (⁶⁷Cu), Scandium-47 (⁴⁷Sc), and Molybdenum-99 (⁹⁹Mo), along with related products. Its core technology involves using high-energy, high-current electron accelerators and specialized equipment, unique technologies, and process flows to simultaneously produce medical isotopes ²²⁵Ac and ²¹²Pb through one irradiation and transmutation of Radium-226 (²²⁶Ra). This addresses the critical issue of China’s complete reliance on imported isotopes such as ²²⁵Ac, while also tackling and disposing of the safety management and risk issues associated with long-lived, highly toxic ²²⁶Ra legacy sources.

 In the research of electron accelerator photonuclear transmutation reaction for ²²⁶Ra, ¹⁰⁰Mo and related technologies, MSTP has conducted theoretical simulation studies of photonuclear transmutation reactions, basic experiments, industrial scale simulation experiments, processing of radioactive radium sources and radon, and radiation protection technologies. A number of independent research and development technologies have been completed including a target preparation system, an automatic system for loading and transferring ²²⁶Ra targets for transmuting, the radio-chemical separation and extraction processes and equipment for simultaneously separation and purification of ²²⁵Ac and ²¹²Pb after the irradiation of ²²⁶Ra target, also the safely handling operations for legacy ²²⁶Ra sources. It holds a significant advantage in this field and being one of the earliest companies in China to systematically conduct research on  photonuclear transmutation technology for producing medical isotopes. In  2021,  the technology won over ten honors including an  Excellence  Award and a  Merit  Award at the first Disruptive Innovation Technology Competition organized by the Ministry of Science and Technology of the People’s Republic of China. It has applied for 20+ patents, with 7 granted, forming an independent production techniques system and an intellectual property “moat”.  

The core team of the company is composed of several senior experts who have long been engaged in nuclear physics, high-energy accelerators, reactor isotope production, radiochemical separation processes, and radiopharmaceuticals development, concluding three internationally renowned experts, multiple national-level innovative leaders, and recipients of the State Council’s Government Allowance.

MSTP’s project “Research on  Electron  Accelerator  Production of  Medical Isotopes and Transmutation Technology” was introduced as a key government project in Mianyang City, Sichuan Province which received multiple policy supports and assistance from the Mianyang municipal government, and has been established in the Nuclear Medical Health Industry Park located in the China Science and Technology City.  The Phase-Ⅰof the project covers an area of  5,351  square meters with a total construction area of approximately 6,241 square meters. The high-energy and high-current electron accelerators and facilities for industrialization has been started to construct. It is scheduled to be completed and into operation by the second half of 2026. Considering an irradiation of 150h of ²²⁶Ra target, the weekly production both of  ²²⁵Ac  (Solution of actinium [²²⁵Ac] nitrate (²²⁵Ac(NO₃)₃) or Dry solid of actinium [²²⁵Ac] nitrate (²²⁵Ac(NO₃)₃) )  and  ²¹²Pb (Solution of lead [²¹²Pb] nitrate (²¹²Pb(NO₃)₂))  will be up to 2-4Ci  and  4-8Ci respectively.